AnaSpec, Monogram Biosciences

AnaSpec this week released its latest series of Protease or Proteinase-Activated Receptors, or PAR, peptides. A total of 17 new PARs were launched.

Monogram Biosciences said this week that beginning July 15 its HERmark Breast Cancer Assay will be available to doctors for assessing HER2 status in patients with breast cancer.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.